AI Spending in M&A: Expense or Capitalized Investment?
Ai Spending Expense Or Investment Ma May 2026: What changed and what advisors are arguing about
On May 4, 2026, Thomson Reuters Tax News flagged a debate that’s been brewing in deal rooms since the One Big Beautiful Bill Act (OBBBA) restored immediate domestic R&E expensing in 2025. The headline is direct: AI spending puts a new question in deal talks — expense or investment? For closely-held sellers, that’s not an academic accounting argument. It’s a real swing on price.
Here’s the setup. A privately-owned company in New York spends $400,000 a year on AI tools. For Ai Spending Expense Or Investment Ma May 2026, some of it is OpenAI API credits piped through a customer support workflow. Some is an in-house data team training a custom model on the company’s pricing history. Some is a Salesforce add-on with a fancy “AI”. Badge. The seller’s CFO booked all of it to “software subscriptions”. On the P&L. The buyer’s Q-of-E firm is now asking whether any of it should have been capitalized, and whether any of it qualifies as §174 specified research or experimental expenditures.
The AI software tax treatment M&A question matters because each path leads to a different EBITDA number and a different tax basis. Capitalize it and EBITDA jumps, since amortization sits below the line. Expense it and EBITDA stays compressed but cash flow looks cleaner. Add §174 into the mix and the seller’s historical tax returns may need to be reopened — which is the last conversation a seller wants to have on the eve of signing.
The AI software tax treatment M&A debate is really three debates stacked on top of each other: a GAAP capitalization question, a tax §174 R&E question, and an EBITDA add-back negotiation. Sellers who haven’t separated these three when they walk into diligence usually lose ground on all three.
Advisors are split. Investment bankers want to capitalize as much as possible because it lifts EBITDA. Tax counsel wants the §174 question answered cleanly so there’s no tail liability. Q-of-E reviewers want the recurring run-rate to reflect what the buyer will actually pay next year, not a one-time training spike. All three positions can be defensible, and that’s exactly why the negotiation gets ugly.
The §174 R&D rule and where AI software lands
A short history. The 2017 Tax Cuts and Jobs Act amended IRC §174 to force capitalization of specified research or experimental expenditures (SRE) starting with tax years after December 31, 2021. Domestic SRE had to be amortized over 5 years. Foreign SRE over 15. Software development was specifically swept in. That single change blew up cash taxes for a wave of tech-adjacent businesses that had been deducting development costs for decades.
Then OBBBA arrived. Beginning in tax year 2025, domestic SRE returned to immediate expensing under a new §174A. Foreign SRE stays on the 15-year capitalization schedule. OBBBA also gave taxpayers a retroactive choice: a small-business taxpayer (under the §448(c) gross receipts test) can elect to treat domestic SRE incurred in tax years 2022, 2023, and 2024 as immediately deductible by filing amended returns or making the change-in-method through Form 3115. Larger taxpayers got a one-time accelerated catch-up over one or two years instead of finishing the 5-year schedule.
So how does AI software actually classify? Three buckets matter for AI software tax treatment M&A analysis:
- §174 specified research or experimental expenditures. Costs incident to development of a software product where there’s uncertainty about capability, method, or design. A custom-trained model, a fine-tuned LLM with proprietary embeddings, or a novel inference architecture usually lands here.
- §167 / §197 capitalized intangibles. A purchased software license with a determinable life, or an acquired AI tool that’s been completed. Amortized over its useful life, or 15 years if acquired in connection with a trade or business under §197.
- Ordinary §162 operating expense. Subscription fees for a finished SaaS product (Microsoft Copilot, ChatGPT Enterprise, GitHub Copilot, a Salesforce Einstein add-on) that the company doesn’t develop or modify. No capitalization, no §174 problem.
The line between bucket one and bucket three is where the AI software tax treatment M&A fight actually happens. A company calling OpenAI’s API support tickets is paying for a finished service — that’s §162 expense. A company hiring engineers to run a multi-month training pipeline on its own customer data, with an uncertain outcome, is doing §174 work even if the underlying model came from Hugging Face. The IRS hasn’t published bright-line rules for this yet. Treasury’s Notice 2023-63 is the closest current guidance, and it predates the OBBBA changes.
If your company has been running AI projects since 2022 and treating everything as §162 software expense, you almost certainly have a §174 exposure to clean up before a sale. The OBBBA retroactive election is a workable fix, but only if your records can support the classification.
The §41 R&D credit is a separate but related story. Spend that qualifies for §41 must also be a §174 expenditure — the credit can’t apply to costs the company expensed as plain §162. So sellers who skipped the §174 file also skipped the §41 credit, leaving real federal money on the table. Form 6765 is the credit form, and it’s one of the first documents a buyer’s tax diligence team will ask for.
How AI tax treatment moves EBITDA and purchase price
Here’s the math nobody likes spelling out, but everybody negotiates around. Imagine a closely-held NYC services business doing $12M of revenue, with $2M of reported EBITDA, going to market at a 7x multiple. Headline price: $14M.
Now layer in $400,000 of annual AI spend that’s been booked as opex. The Q-of-E firm walks in and asks two questions: how much is recurring? And how much should be capitalized? Take three scenarios.
Scenario A — everything stays as opex. EBITDA is $2.0M. Multiple of 7x. Price $14.0M. Clean, defensible, no add-backs. Buyer is happy. Seller leaves $2.8M on the table relative to scenario B.
Scenario B — $400K reclassified as capitalized AI investment. EBITDA jumps to $2.4M. Same 7x multiple. Price $16.8M. Seller likes this a lot. Buyer pushes back hard because future maintenance and retraining costs will hit the new owner’s P&L anyway, and the 7x multiple bakes in the assumption that those costs are recurring.
Scenario C — split. $250K capitalized (the actual model-training payroll and the fine-tuning project), $150K stays as opex (the API calls, the SaaS subscriptions). EBITDA lifts to $2.25M. Price $15.75M. This is where most deals land after a real fight.
The AI software tax treatment M&A delta between scenarios A and C is $1.75M of purchase price — on a $400K spend item. That’s why this debate isn’t a footnote. It’s the deal.
The tax basis side of the trade matters too. Capitalized investment creates basis the buyer inherits (in an asset deal) or sits inside the target’s E&P (in a stock deal). Future amortization of that basis reduces taxable income for the buyer. Buyers usually pay something for that, but they pay less than the EBITDA multiple suggests. A $250K capitalized intangible amortizing over 5 years gives the buyer roughly $50K of annual deductions, worth about $11K a year at a 21% federal rate — present-value maybe $40K to $45K. Far less than the $1.75M of EBITDA-driven price lift. That gap is exactly what buyers exploit when they push back on AI software tax treatment M&A add-backs.
Common mistakes — what we see every year in Q-of-E
We see this every year on the sell-side. A founder spends three years building something interesting with AI, lands a buyer, then watches the diligence team strip price out of the deal because the back-office paperwork doesn’t match the technical story. Five recurring patterns:
1. Year-end reclassifications with no contemporaneous file. The CFO scrambles in December to move “AI development”. From opex to a capitalized intangible, but there are no project codes, no payroll allocations, no experiment logs. The reclass sits on the trial balance with nothing behind it. A buyer’s Q-of-E team calls that adjustment what it is — a paper move — and refuses the add-back.
2. AI tools dropped into “software subscriptions”. Indiscriminately. Every line item from a $20-a-month ChatGPT Plus seat to a $200K annual contract for a custom-trained vertical model lands on the same GL account. A buyer reviewing AI software tax treatment M&A questions can’t tell the SaaS from the SRE. The default assumption then becomes “all opex,”. And any seller-favorable reclass gets pushed into earnouts or escrow.
3. Capitalized AI without a credit study. A company decides retroactively that $300K of engineering payroll was §174 software development, but never did the §41 R&D credit work. So the company ate the 5-year capitalization hit (back when TCJA forced it) without claiming the credit that was sitting right next to it. That’s leaving 6–10% of qualified spend — real cash — uncollected.
4. Sellers forgetting §174(d) recapture on a subsequent disposition. If capitalized SRE gets disposed of, retired, or abandoned mid-amortization, §174(d) requires the unamortized balance to keep amortizing — you can’t accelerate the deduction. Sellers think they’ve baked in a deduction stream and find out at closing it can’t be sped up.
5. Skipping the OBBBA retroactive election analysis entirely. Many small-business sellers can elect to treat 2022–2024 domestic SRE as immediately deductible by filing amended returns. That can throw off significant refunds — cash that lands in the seller’s pocket pre-close. Almost nobody runs the math before going to market. The buyer’s tax team finds it, points it out as a buyer benefit, and uses it to chip the price.
If your AI software tax treatment M&A diligence binder doesn’t include a project-level §174 file, a §41 credit study, and a written OBBBA retroactive election analysis, you’ll get out-negotiated on price. Buyers know what’s missing. Sellers usually don’t.
What to fix before listing your business for sale
For NYC closely-held business owners targeting a sale in the second half of 2026 or in 2027, the AI software tax treatment M&A workstream needs to start at least nine months before signing. Here’s the checklist we run with sell-side clients on our business management and tax strategy services:
- Map every AI-related cost. Pull three years of GL detail. Group by vendor, by project, by cost type (subscription, payroll, contractor, hardware, cloud compute). Don’t trust the GL account names — they lie.
- Classify each bucket. §162 opex, §174 SRE, §167/§197 acquired intangible. Document the why, in writing, at the project level. A two-paragraph memo per project is enough.
- Run the OBBBA retroactive election analysis. If you’re under the §448(c) gross receipts test, model the cash from amending 2022–2024. If amend math is positive, file before you sign — refunds belong to the seller.
- Build a §41 credit study for years still open under statute. The credit follows the §174 file. If you’re already doing the §174 work, the credit is mostly free.
- Pre-build the EBITDA add-back schedule. Quantify exactly which AI costs are nonrecurring (training, one-time fine-tuning, proof-of-concept work) and which are run-rate. The seller who shows up to Q-of-E with this prepared controls the conversation.
- Get rep &. Warranty insurance underwriters comfortable. RWI carriers are now asking specific questions about §174 compliance. A clean file means cheaper coverage and a thinner exclusion schedule.
- Coordinate with your corporate tax return preparer. The position on the M&A schedule has to match what’s been filed historically. Don’t let the deal team and the tax team work in parallel without a reconciliation.
That’s it. Seven steps. None of them are exotic. The companies that walk through this checklist before listing get materially better outcomes than the ones that don’t — and the difference is almost always larger than the cost of the work.
How The Reed Corporation works with NYC sellers on AI software tax treatment M&A
We work with closely-held business owners across New York City who are 6–24 months out from a transaction. Our role on AI software tax treatment M&A questions sits at the intersection of tax and operating finance — we build the §174 file, run the OBBBA election math, prepare the EBITDA add-back schedule, and sit across from the buyer’s Q-of-E team during diligence. The work blends with our business management service, our tax strategy practice, and our corporate tax return preparation.
If you’re thinking about a sale and you’ve been running real AI spend through your P&L, the conversation we’d want to have first is short. What did you spend, on what projects, with what documentation? From there we can tell you in a week whether the AI software tax treatment M&A position you’d take in diligence will hold up — and what the upside looks like if you fix the file before the buyer sees it. More background on related topics sits in our helpful guides.
Related Services from The Reed Corporation
Helpful Guides You Might Also Like
Sources & References
Frequently Asked Questions
Is my company’s AI software spend §174 R&D or operating expense for AI software tax treatment M&A purposes?
The honest answer: it depends on what your engineers and contractors actually did, not what the invoice line said. The starting point for any AI software tax treatment M&A analysis is the §174 statutory definition. IRC §174 covers specified research or experimental expenditures — meaning costs that are paid or incurred in connection with the taxpayer’s trade or business and that represent research and development costs in the experimental or laboratory sense. Treasury’s Notice 2023-63 expanded that definition to explicitly include software development. If your team is writing code with uncertainty about capability, methodology, or design, the spend is §174 territory.
Apply that test to AI specifically. Buying API access to a finished model and piping the output into a deterministic workflow isn’t research. There’s no uncertainty — you call the API, you get a response, you display it. That’s a §162 operating expense, full stop. The AI software tax treatment M&A position on those costs is straightforward: opex, recurring, nothing capitalized.
Now flip the example. Your data team takes an open-source base model and fine-tunes it on three years of your proprietary customer data. They run dozens of training experiments, change hyperparameters, throw out half the runs, and end up with a custom model that does something the off-the-shelf product couldn’t. That work has uncertainty — nobody knew at the start whether the fine-tuning would converge to something useful. That’s a textbook §174 specified research or experimental expenditure, and the AI software tax treatment M&A position should reflect it.
Most companies sit somewhere in the middle. They’ve got a ChatGPT Enterprise subscription (§162), a Salesforce Einstein add-on (§162), an internal RAG pipeline built on top of vector embeddings (probably §174), and a custom model training project (definitely §174). The AI software tax treatment M&A workstream needs to break each cost down by project and apply the test individually. Don’t let one bucket contaminate another.
The §41 R&D credit interaction is where this gets interesting. Costs that qualify for the §41 credit must also be §174 expenditures. The four-part test under Form 6765 instructions — permitted purpose, technological in nature, elimination of uncertainty, process of experimentation — lines up almost perfectly with serious AI development work. So if you’ve identified $300K of §174 AI spend, you’ve also probably identified $300K of qualified research expenditure for credit purposes. At a typical 6–10% effective credit rate, that’s $18K to $30K of federal credit per year — before any state-level credit. New York State has its own R&D-adjacent program. The AI software tax treatment M&A diligence binder should include the credit math, not just the deduction math, because buyers value those credits when they roll forward.
One concrete example clients ask about constantly: LLM API calls versus custom model training. A company spending $100K a year on OpenAI API credits to power a customer support bot has zero §174 exposure on that line. The AI software tax treatment M&A position is “ordinary and necessary business expense, deductible in the year incurred under §162.” Done. Now take the same company and add a $200K initiative where in-house engineers train a domain-specific embedding model on the company’s documentation. That second project is §174 SRE. Different treatment, different tax basis, different EBITDA implication, all in the same fiscal year. The mistake we see is teams that lump both projects under one GL account and treat them identically.
For sell-side AI software tax treatment M&A diligence, the practical workflow is: pull every AI-related invoice and payroll allocation for the last three years, sort each line into one of three buckets (§162 finished service, §174 development, §167/§197 acquired asset), and write a one-paragraph memo justifying each §174 classification. The memo isn’t optional. Buyers and Q-of-E firms ask for it, RWI carriers ask for it, and the IRS asks for it on audit. Without those memos, the AI software tax treatment M&A position falls apart under scrutiny and you lose the deduction or the credit or both.
The opinionated take: most closely-held companies in NYC that have been running AI projects since 2022 have under-classified their §174 spend, not over-classified it. They’ve been treating everything as opex because it was easier and because the GL account naming made it invisible. When sale conversations start, that under-classification becomes a one-way ratchet down on price — the buyer gets the upside of “this should have been capitalized, increase EBITDA”. Math without paying for it, because the seller can’t document it. Fix this nine months before you list, not nine days.
One more nuance worth flagging. Software developed for sale, lease, or licensing to others is treated differently than software developed for internal use, and the AI software tax treatment M&A analysis has to account for that. A SaaS company that builds AI features into its product line is generally on stronger §174 ground than a services firm that builds an AI tool for internal productivity. The substantive test is the same. The documentation expectations are tougher for internal-use software, because the IRS has a longer history of policing that boundary. If your sale story leans on capitalized AI, make sure the use-case fits the storyline. Buyers’. Counsel will check.
One last point on classification, because it trips up nearly every closely-held seller we work with. Cloud compute is its own category. AWS and GCP bills attached to training runs are part of the §174 SRE pool when the underlying project is §174. Cloud compute attached to ordinary production traffic is plain §162 hosting. The same vendor invoice may carry both. AI software tax treatment M&A files that survive diligence break the cloud bill apart by project and tag — usually with the same cost-allocation labels the engineering team uses internally. Don’t let your bookkeeper code the whole AWS invoice to “hosting”. And call it done. The audit trail has to follow the dollars to the workstream that consumed them, and a buyer’s Q-of-E team will absolutely test a sample of those allocations against what your engineers say they were doing in any given month. Showing up with messy compute allocations is a fast way to lose the credibility you built with the rest of the file.
How does AI software tax treatment in M&A change my EBITDA and sale multiple?
The AI software tax treatment M&A question moves price through two levers: the EBITDA add-back lever and the tax-basis lever. The first is a multiple-driven number. The second is a present-value number. Buyers know which one is bigger and they’ll lean on whichever one favors them.
Start with EBITDA. Capitalized investment doesn’t hit EBITDA — amortization sits below the operating-income line. So if you reclassify $400K of AI spend from operating expense to a capitalized intangible asset, EBITDA goes up by $400K. At a 7x multiple, that’s $2.8M of headline price. At a 10x multiple (for a higher-quality recurring-revenue business), it’s $4M. The AI software tax treatment M&A reclass has the highest use of any single accounting decision a seller will make in the run-up to a deal.
But buyers aren’t dumb. The Q-of-E team will challenge every dollar of that reclass. The challenge usually takes one of three forms. First, “is this really capitalizable under GAAP?” — a question about the underlying ASC 350-40 internal-use software guidance or ASC 985-20 software-to-be-sold guidance. Second, “is this recurring or nonrecurring?” — a question about whether the AI spend will repeat next year regardless of how it’s accounted for. Third, “is the tax position consistent with the GAAP position?” — a question about whether the seller has been treating the same dollars one way for tax and another for book.
Sponsor-side buyers (private equity) tend to fight harder on AI software tax treatment M&A add-backs than strategic buyers. PE buyers are pricing off a used multiple where every turn of EBITDA matters to their returns model. Strategic buyers are usually pricing off combined benefits and have more tolerance for accounting normalization. The same $400K reclass that a strategic accepts at 80 cents on the dollar might get pushed back to 30 cents on the dollar by a sponsor.
Here’s a real-world AI software tax treatment M&A negotiation pattern. Seller proposes $400K capitalized, EBITDA up $400K. Buyer’s Q-of-E firm normalizes back $150K of the spend as recurring run-rate (because the maintenance and retraining will happen every year). Buyer also pushes $100K back to opex on the grounds that the documentation doesn’t support capitalization. Final reclass: $150K stays capitalized. EBITDA lift: $150K, not $400K. Price lift at 7x: $1.05M, not $2.8M. The seller loses 62% of the headline price improvement during diligence. That’s typical.
The tax-basis lever is the second-order story. When AI spend gets capitalized for GAAP, it usually also gets capitalized for tax under §174 (or §167/§197). That capitalized amount creates basis that the new owner can amortize against future income. In an asset deal, the buyer inherits that basis directly — and a smart buyer will pay for it. In a stock deal, the basis sits inside the target and survives in the form of future tax shields. The AI software tax treatment M&A negotiation has to track which deal structure is on the table and price the basis so.
The math: a $250K capitalized intangible amortizing over 5 years gives the buyer $50K of deduction per year, worth about $11K of cash tax savings at the 21% federal rate (more if you add state). Present-value that stream at 8% and you get roughly $44K. Compare that $44K to the $1.75M of headline price the seller captured by reclassifying the same $250K to capitalized investment, and you see why buyers happily concede the basis point but fight the EBITDA point. The AI software tax treatment M&A purchase-price impact is dominated by the EBITDA multiplier, not the tax shield.
One nuance buyers exploit constantly: the recurring-vs-nonrecurring distinction. Even if a cost is properly capitalized for GAAP and tax, if it’s part of a recurring spend pattern (year after year of model retraining, for example), buyers argue it should still be subtracted from the EBITDA add-back because the new owner will incur the same spend from now on. The AI software tax treatment M&A add-back schedule needs to anticipate this argument by separating one-time projects (initial build, big migrations) from ongoing maintenance.
The opinionated take: don’t go to market with a single-number AI software tax treatment M&A position. Build a range. Show the most defensible reclass at the bottom, the aggressive reclass at the top, and explain in writing why each line item belongs where it does. Buyers respect a seller who’s done the work, even when they’re trying to push the number down. And RWI carriers will price coverage off the documentation quality, not the number itself. A clean file at $200K of reclass usually beats a sloppy file at $400K, because the sloppy file blows up under stress and turns into a price chip the seller can’t defend.
Last point on multiples specifically: the multiple itself can move based on AI software tax treatment M&A signals. A buyer who sees a clean §174 file, a real §41 credit study, and proper documentation reads “professional management”. And may pay a quarter-turn higher multiple on the entire EBITDA number, not just the AI piece. A buyer who sees chaos reads “execution risk”. And discounts the whole company. The AI software tax treatment M&A workstream is so not just about the AI numbers — it’s a signal about the rest of the back office.
One specific structural trap to flag: the buyer’s letter of intent (LOI) often locks in the EBITDA definition before AI software tax treatment M&A diligence gets serious. If the LOI defines EBITDA as “consistent with historical accounting practices,”. You’ve handed the buyer a tool to reject every reclass on the grounds that it isn’t “historical.” The seller-favorable LOI language is “EBITDA as defined and adjusted in accordance with the quality-of-earnings analysis to be conducted.” That’s a small drafting change that opens the door to legitimate add-backs. Sellers who don’t think about AI software tax treatment M&A implications until after the LOI is signed have already lost meaningful use. Get the working definition right at LOI — before exclusivity locks the deal in — and you preserve the ability to argue your reclass on the merits rather than getting blocked at the threshold question of what counts as a permitted adjustment.
What documentation does a buyer’s Q-of-E review want for AI software tax treatment in M&A?
The Q-of-E firm wants enough paper to defend the seller’s position to three audiences: their own client (the buyer), the rep &. Warranty insurance carrier, and the IRS in a future audit. The AI software tax treatment M&A documentation expectations have gotten sharper over the last 18 months as §174 audit activity ramped up post-TCJA.
The minimum file we build for AI software tax treatment M&A diligence has six categories. None of them are optional once a serious buyer is at the table.
First, project-level identification. Every AI initiative gets a project code, a written description, a start date, an end date (or “ongoing”), and a category (R&E, finished SaaS, acquired tool). The description has to be specific enough that someone outside the company can read it and understand what was being built and what the technical uncertainty was. “AI improvements to customer service”. Doesn’t cut it. “Fine-tuning a Mistral 7B base model on 18 months of support ticket transcripts to reduce average handle time, with experimentation on RLHF parameter values to improve tone consistency”. Does cut it. The AI software tax treatment M&A binder lives or dies on this level of specificity.
Second, payroll allocation. For employees who worked on §174 projects, you need a contemporaneous record of their time. Best practice is monthly timesheet allocation by project, kept by the employee. Acceptable practice is quarterly allocations with manager sign-off. Unacceptable practice (which is what most companies actually have) is a single year-end estimate that an outside accountant pulled together by guessing percentages. Q-of-E firms reviewing AI software tax treatment M&A files reject the year-end estimate approach almost universally now.
Third, contractor and vendor invoices. Every contractor doing §174 work needs a statement of work that describes the project at the same specificity level as the internal project description. Cloud compute and training infrastructure invoices need to be tagged to the project that consumed them — AWS or GCP cost-allocation tags work for this if they’re enabled. The AI software tax treatment M&A reviewer will tie compute spend to project documentation. If the spend is there but the project description isn’t, the dollars get reclassified back to opex.
Fourth, experiment logs and technical artifacts. This is where the §174 “process of experimentation”. Element shows up in real evidence. Code repositories with branches, commit messages, and pull-request comments. Notebooks documenting failed training runs. Slack channels where the team debated approach. The AI software tax treatment M&A position on a project as §174 SRE is enormously stronger when there’s a paper trail showing real iteration and uncertainty resolution. A clean linear development path that worked on the first try doesn’t usually qualify as §174 — the whole point is the experimentation.
Fifth, the §41 credit study. If the company is also claiming the R&D credit, the AI software tax treatment M&A documentation expands to include the four-part test analysis for each project, qualified research expenditure calculations, and base-period analysis (or alternative simplified credit calculation) on Form 6765. Most Q-of-E firms have a tax-credit specialist who reviews this section separately. A weak §41 file is one of the easiest places for buyers to chip the price, because if the credit isn’t supportable, the seller has been over-stating after-tax cash flow for years.
Sixth, the OBBBA election analysis. Whether or not the seller elected the retroactive immediate-expense treatment for 2022–2024, the file should include a written analysis of the election — the taxpayer’s eligibility, the cash impact at different scenarios, the reason the election was or wasn’t made, and the change-in-method posture (Form 3115 if applicable). The AI software tax treatment M&A diligence team treats absence of this analysis as a red flag.
The rep &. Warranty insurance carrier reviews the same file with a slightly different lens. RWI underwriters are pricing the probability of a tax adjustment after closing. They want to see that the §174 positions were taken with a more-likely-than-not (or higher) standard, that the contemporaneous documentation supports the position, and that the tax provision was set up correctly on the closing balance sheet. AI software tax treatment M&A files that survive RWI underwriting cleanly tend to also survive Q-of-E cleanly — the standards are aligned.
One practical point: do this work on rolling basis, not at the deal table. The AI software tax treatment M&A documentation that gets built six weeks before signing always looks worse than documentation that was built contemporaneously over three years. Even when the substance is identical, the optics aren’t. Buyers who see a binder that was clearly assembled in a panic discount the positions inside it. Buyers who see contemporaneous monthly files trust the positions and move on.
The opinionated take: if your company spends more than $200K a year on AI development and you’re within 24 months of any potential transaction, the AI software tax treatment M&A documentation work pays for itself many times over. The cost of building the file in real time is roughly the cost of one outside tax-credit study per year. The cost of not building it shows up as price erosion in diligence, RWI exclusions, and post-close tax indemnity exposure. The math isn’t close.
A few extra documentation pieces that show up in serious deal rooms but rarely on smaller transactions: board minutes referencing the AI initiatives (especially helpful for §174 substantiation when the project crosses a budget threshold that required board approval), employment agreements or contractor agreements that specifically describe the research nature of the work, and any patent or trade-secret filings that flow from the work. None of these are required for the AI software tax treatment M&A position to hold, but each one strengthens the file when it’s there. RWI carriers in particular treat patent filings as near-conclusive evidence of technological uncertainty — you don’t file a patent on something that already worked. If your engineering team has any IP filings tied to the AI projects, pull them into the diligence binder. They cost nothing to add and they raise the underwriter’s confidence in the position more than three more pages of project memos would.
Should I make the OBBBA retroactive §174 election before selling — and how does it affect AI software tax treatment in M&A?
The short answer: usually yes, if you’re eligible, and the cash from amending lands in the seller’s pocket pre-close. But the analysis isn’t automatic, and there are real cases where the AI software tax treatment M&A negotiation gets harder if you make the election sloppily. Here’s the framework.
OBBBA, enacted in 2025, restored immediate expensing of domestic specified research or experimental expenditures effective for tax years beginning after December 31, 2024. The same statute gave eligible small-business taxpayers (those meeting the §448(c) average gross receipts test — under $30M for tax years beginning in 2025, indexed) a retroactive choice. They can elect to treat domestic SRE incurred in tax years 2022, 2023, and 2024 as immediately deductible by either filing amended returns for those years or making an automatic change in method on Form 3115. Larger taxpayers got a separate one- or two-year catch-up rather than a full retroactive option.
The cash math is usually positive for sellers. Take a NYC closely-held services business that spent $300K of qualifying domestic SRE per year from 2022 through 2024. Under the original TCJA §174 rule, that company capitalized and amortized over 5 years, deducting only $30K in year one (mid-year convention), $60K in year two, $60K in year three. Total deduction taken across 2022–2024 was $150K out of $900K spent. The remaining $750K was sitting on the books amortizing into the future.
Make the OBBBA retroactive election and that flips. The full $900K becomes deductible in the years it was incurred. Net incremental deduction across 2022–2024: $750K. At a 37% federal pass-through rate plus NYC’s combined state and local rate, the cash refund or carryforward is meaningful — often $300K to $400K depending on the structure. That cash belongs to the seller, not the buyer, because the income tax years being amended are pre-close years.
So why isn’t this automatic? Three reasons matter for AI software tax treatment M&A planning.
Reason one: the election interacts with §41. The R&D credit base-period calculation and current-year credit can shift when you change the §174 method. If you’ve been claiming the credit consistently with your old §174 position, the election may force a coordinated amendment of the credit returns too. The AI software tax treatment M&A workstream has to reconcile both. Done right, the credit usually still claims correctly — sometimes for more — but the paperwork gets bigger.
Reason two: state conformity is a mess. Some states automatically conform to federal §174 rules. Others decoupled when TCJA forced capitalization, and now have to decouple again from the OBBBA reversal — or haven’t acted yet. New York State’s specific posture on the OBBBA §174 reversal is evolving, and an aggressive federal election can create a state-level position that doesn’t match. The AI software tax treatment M&A diligence team will check both. Don’t make the federal election without modeling the state.
Reason three: the change-in-method posture itself. If you go the Form 3115 route instead of amended returns, the resulting §481(a) adjustment hits the year of change. That can spike taxable income or create a refund timing wrinkle that doesn’t line up with the deal calendar. A careful AI software tax treatment M&A advisor will pick the path (amend versus 3115) based on which one lands the cash before closing.
Now the deal-side question: how does the election change the AI software tax treatment M&A negotiation? Three effects.
First, basis. Once you elect immediate expensing, the previously capitalized SRE is gone — no future amortization for the buyer to inherit. That removes one of the buyer’s price-discounting arguments (the “we’ll inherit the basis anyway”. Line) but also removes a buyer-side benefit. Net effect on price is usually small, but it matters for the asset-versus-stock structure analysis.
Second, EBITDA cleanliness. With the election made, the seller’s historical financial statements (book) and tax returns (tax) line up more cleanly — both show the SRE as expensed. That makes the AI software tax treatment M&A narrative simpler in diligence: “we expensed it for both purposes, here’s the consistent treatment.” Buyers like consistency. They distrust mismatched book-tax positions even when the mismatch is technically correct.
Third, working-capital and tax-receivable mechanics. If the election produces a federal refund that hasn’t been paid by closing, that refund usually rolls into the closing-date tax receivable and gets settled separately as part of the purchase agreement. The AI software tax treatment M&A purchase agreement language has to specify who owns the refund — almost always the seller, but only if the agreement says so explicitly.
When does the election hurt? Mostly when the seller’s expected post-deal residency or rate environment changes. If the seller is moving from a high-tax state to a no-tax state immediately after closing, accelerating deductions into pre-close years (when they’re at higher rates) is good. If the seller will roll some equity into the buyer’s structure and stay involved, the timing analysis changes. For pure cash-out NYC sales the answer is almost always to elect, document the election cleanly, get the refund cycle started, and walk the AI software tax treatment M&A position into diligence with the file already settled.
The opinionated take: every NYC closely-held seller eligible for the OBBBA retroactive §174 election should run the math six months before listing. The math doesn’t take long. The cash impact is real. And the AI software tax treatment M&A diligence story gets materially cleaner when the historical position is settled and consistent rather than open and ambiguous.
A timing note worth flagging. The OBBBA election windows aren’t open forever. The amended-return path generally has to be filed within the standard three-year statute window from the original filing date, and the Form 3115 change-in-method route has its own filing-date constraints tied to the year of change. Sellers who delay the AI software tax treatment M&A election analysis until after they’ve signed an LOI sometimes discover that the cleanest cash-collection path has already closed. The 2022 tax year is the one to watch — for many calendar-year filers the amend window for that year closes in 2026, which is exactly when a lot of these transactions are landing. If you’re in any way considering a sale this year or next, run the OBBBA election math in the next 60 days, not after the deal closes.
If my buyer pushes back on AI software tax treatment in M&A, what concessions can I offer?
Pushback happens in nearly every deal. The AI software tax treatment M&A position the seller wants is rarely the position the buyer accepts at full value. The good news: there’s a deep menu of concessions that don’t cost the seller most of the headline price. The skill is knowing which concession to offer and when.
Start with the structure of the pushback. Buyers usually attack AI software tax treatment M&A positions on one of four axes: classification (is it really §174?), recurrence (will it happen again next year?), documentation (can you prove it?), or downstream tax exposure (will the IRS reverse this on audit?). Each axis has a different concession that fits.
Concession one: the working-capital peg. If the dispute is about whether AI spend is recurring or nonrecurring, sellers can agree to set the working-capital peg using a normalized run-rate that includes the spend, while still preserving the EBITDA add-back. The buyer gets protection against a post-close cash drain. The seller keeps the multiple-driven price lift. This is one of the cleanest AI software tax treatment M&A trades because each side gets what they want most.
Concession two: indemnity escrow specific to §174. Sellers can offer a tax indemnity carve-out for §174 positions, with a defined escrow percentage (usually 1–3% of purchase price) and a defined release schedule (often 18–24 months, lining up with the typical IRS examination window). This works when the dispute is about downstream tax exposure rather than book accounting. Buyer gets protected against a future IRS adjustment. Seller doesn’t take a price chip up front.
Concession three: rep &. Warranty insurance with a tax-specific underwrite. RWI carriers will write coverage on §174 positions if the documentation supports it. The cost runs 3–5% of the limit. Sellers can offer to pay for an improved tax wrapper as a price-preserving concession. This is the AI software tax treatment M&A concession that comes up most often in deals over $50M.
Concession four: post-close §174 adjustment language. The purchase agreement can include language requiring the buyer to take a specified position on §174 in post-close tax filings, or to coordinate with the seller before any IRS examination of pre-close periods. This protects the seller’s tax indemnity against being accidentally weakened by the buyer’s post-close behavior. It’s a soft AI software tax treatment M&A concession that costs the buyer almost nothing but matters a lot if a controversy comes.
Concession five: pricing concession scaled to documentation gap. If the AI software tax treatment M&A position is sound but the documentation is genuinely thin, sellers can offer a small price concession (say, 1–2% of enterprise value) in exchange for the buyer accepting the position without further chip. This works when the seller knows the position is right but doesn’t have time to rebuild the file before signing. Better to take the small chip than fight at the deal table over documentation.
Concession six: earnout or contingent value right tied to credit recovery. If the §41 credit position is what’s being attacked, sellers can structure a contingent payment that flows back to the seller if and when the credit is sustained on audit (or the audit window closes without challenge). Buyers like this because it puts the seller’s skin on the position. Sellers like it because they keep the upside if they were right. The AI software tax treatment M&A negotiation often resolves on this kind of structure when the parties just disagree about probability.
Concession seven: rep enhancements. Sometimes the buyer’s worry isn’t a number, it’s risk allocation. Sellers can give a tighter set of tax representations (specifically calling out §174 method, §41 credit, and OBBBA election) without conceding price. This is paper-only and cheap. The AI software tax treatment M&A reps that show up in modern deal templates have gotten more specific over the last two years. Sellers should expect this and have model language ready.
What sellers should not concede, generally: large EBITDA reclassifications driven by aggressive buyer interpretations, tax indemnities without dollar caps, or open-ended buyer control over post-close tax positions. Those concessions compound — they keep costing the seller money for years. The AI software tax treatment M&A concession menu has cleaner trades than these on it. Pick those instead.
One pattern we see in NYC closely-held sales specifically: when the buyer is a strategic acquirer with a strong tax department, the AI software tax treatment M&A pushback is usually rigorous and grounded. When the buyer is a sponsor working with a generic Q-of-E firm, the pushback is often template-driven and not always defensible. Sellers should test the buyer’s specific objection before conceding. Asking “what’s the technical authority you’re relying on for that adjustment?”. Is a fair question, and a meaningful share of the time the answer reveals that the buyer’s position is weaker than it looked.
The opinionated take: most AI software tax treatment M&A disputes settle at 40–60% of the seller’s initial position, not the seller’s full ask and not the buyer’s full chip. Going in with a clean file and a defensible story gets you to the high end of that range. Going in with a panic-built binder gets you to the low end. The work to move from one outcome to the other is mostly done in the nine months before signing — not in the four weeks of formal diligence. Sellers who plan so capture six- and seven-figure swings on deals that look identical on the surface.
One last move sellers underuse: bring the buyer’s specific objection back to your accountants and tax counsel before responding. Buyers will often float an aggressive position to test the seller’s resolve, and if you concede in real time at the deal table, you’ve ratified that position permanently. AI software tax treatment M&A objections are technical enough that almost no buyer expects an immediate answer — taking 48 hours to respond with a written memo signals competence and frequently moves the buyer’s position toward yours by the time the next call happens. Slow is fast in tax diligence. The sellers who walk away from the table to think usually come back with more price than the sellers who try to handle every chip live.